Skip to main content
Erschienen in: Osteoporosis International 11/2006

01.11.2006 | Original Article

Persistence with teriparatide in patients with osteoporosis: the UK experience

verfasst von: N. K. Arden, S. Earl, D. J. Fisher, C. Cooper, S. Carruthers, M. Goater

Erschienen in: Osteoporosis International | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The objective of this paper was to determine the persistence with teriparatide at 12 months in all patients in the UK who were prescribed the treatment since its launch.

Methods

Virtually all patients prescribed teriparatide in the UK receive treatment through Healthcare at Home, Basingstoke, UK. Data was obtained to assess the start date, discontinuation date and reason for discontinuation in all patients receiving teriparatide since its launch. Persistence was defined as the number of patients continuing treatment.

Results

A total of 1,104 patients were included in the analysis. The median duration of use in all patients was 252 days. Of the 435 patients who were at least 12 months post-initiation of treatment, persistence was 87%. Forty-two patients (3.8%) had discontinued treatment due to adverse events.

Conclusions

This study demonstrates that persistence with teriparatide at 12 months is very high and is probably greater than that of existing oral therapies for osteoporosis. The reasons for the high persistence rates seen with teriparatide are likely to be multi-factorial. The high persistence rates should help to optimise the effectiveness of therapy in this group of high-risk patients.
Literatur
1.
Zurück zum Zitat Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2A):12S–17SPubMedCrossRef Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2A):12S–17SPubMedCrossRef
2.
Zurück zum Zitat Bocuzzi SJ, Folz SH, Omar MA, Kahler KH (2005) Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 16(Suppl 3):Abstract OC10 Bocuzzi SJ, Folz SH, Omar MA, Kahler KH (2005) Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int 16(Suppl 3):Abstract OC10
3.
Zurück zum Zitat Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460PubMedCrossRef Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460PubMedCrossRef
4.
Zurück zum Zitat McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3):271–287PubMedCrossRef McCombs J, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3):271–287PubMedCrossRef
5.
Zurück zum Zitat Cano A (1994) Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 20(2–3):91–99PubMedCrossRef Cano A (1994) Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 20(2–3):91–99PubMedCrossRef
6.
Zurück zum Zitat Kotzan JA, Martin BC, Wade WE (1999) Persistence with oestrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy 19(3):363–369PubMedCrossRef Kotzan JA, Martin BC, Wade WE (1999) Persistence with oestrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy 19(3):363–369PubMedCrossRef
7.
Zurück zum Zitat NICE (2004) Secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, England, June 2004 NICE (2004) Secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, England, June 2004
8.
Zurück zum Zitat Sackett DL, Snow JC (1981) Magnitude of compliance and non-compliance. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. Johns Hopkins University Press, Baltimore, Maryland, pp 11–23 Sackett DL, Snow JC (1981) Magnitude of compliance and non-compliance. In: Haynes RB, Taylor DW, Sackett DL (eds) Compliance in health care. Johns Hopkins University Press, Baltimore, Maryland, pp 11–23
9.
Zurück zum Zitat Papaioannou A, Ioannidid G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14(10):808–813PubMedCrossRef Papaioannou A, Ioannidid G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14(10):808–813PubMedCrossRef
10.
Zurück zum Zitat Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117–1123PubMedCrossRef Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89(3):1117–1123PubMedCrossRef
11.
Zurück zum Zitat Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14(3):259–262 Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 14(3):259–262
12.
Zurück zum Zitat Kelly R, Taggart H (1997) Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 315(7117):1235PubMed Kelly R, Taggart H (1997) Incidence of gastrointestinal side effects due to alendronate is high in clinical practice. BMJ 315(7117):1235PubMed
Metadaten
Titel
Persistence with teriparatide in patients with osteoporosis: the UK experience
verfasst von
N. K. Arden
S. Earl
D. J. Fisher
C. Cooper
S. Carruthers
M. Goater
Publikationsdatum
01.11.2006
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 11/2006
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-006-0171-5

Weitere Artikel der Ausgabe 11/2006

Osteoporosis International 11/2006 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.